Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Biosensor Platform Developed for POC Diagnosis of Cerebrovascular Disease

By LabMedica International staff writers
Posted on 27 Apr 2011
A consortium has been formed to develop an immunoassay detection device for the diagnosis of cerebrovascular disease. More...


The device has to be standalone so that it may be used for emergencies such as when diagnosis is required in an ambulance, emergency room, or as part of a rapid near-patient laboratory test in a hospital environment. Therefore, a number of key processes must be completed automatically within the system. The biosensor platform needs to be able to manipulate liquid samples and deliver any biomarkers that are present to the surface of the sensor in a manner that ensures accurate and reliable detection.

The EUR 3.6-million P3SENS consortium project, which is being coordinated by Multitel (Mons, Belgium), has been making good progress. The aim of the project is to design, develop, and manufacture robust microfluidic systems that can be used for fast and cost-effective sample transport and that also contain simple sample preparation functions.

Preliminary microfluidic structures have been designed taking into consideration the proposed layout of the sensor chip and the material requirements. The microfluidics system is to contain six parallel individual channels with different components supplying the integrated functions of washing and mixing.

Members of the consortium include: The Research Institute for Technical Physics and Materials Science (MFA, Budapest Hungary), which is mainly responsible for the immobilization and optical characterization of receptor protein layers using label-free optical waveguide based sensors, and for the manufacture of the microfluidic polymer structure; and a Center for Micro and Nanotechnology located in Micronova (Finland) and run jointly by VTT Technical Research Center of Finland (VTT; Finland) and Aalto University (Finland). VTT's main responsibilities in the project are the development of nanoimprint lithography (NIL) for patterning waveguides and photonic crystals into the polymer, the design and fabrication of NIL-based photonic chips, and the integration of photonic and fluidic functions in a single chip. Other institutes in the consortium include The Biomedical Proteomics Research Group (BPRG) at Geneva University (Switzerland); The James Watt Nanofabrication Center (JWNC) in Glasgow University (Scotland); Bayer Technology Services GmbH (Leverkusen, Germany); and Stratophase, a VC-funded spin-out from the University of Southampton in (UK).

Related Links:

P3SENS consortium project
Multitel
The Research Institute for Technical Physics and Materials Science
Center for Micro and Nanotechnology
VTT Technical Research Center of Finland
Aalto University
Biomedical Proteomics Research Group (BPRG) at Geneva University
The James Watt Nanofabrication Center (JWNC) in Glasgow University
Bayer Technology Services GmbH
Stratophase



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.